Concepedia

Author

Karen Mezzi

Novartis (Switzerland)

Also Known As

K Mezzi, K. Mezzi, KAREN MEZZI, Karen Mezzi, S Byrne

79

Publications

590

Citations

14

H-Index

49

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Uppsala UniversityImperial College LondonKarolinska Institutet
KM

About

Karen Mezzi is an author at Novartis (Switzerland) specializing in medicine, public health, and pulmonary medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

110

2

Public Health

3

3

63

3

Arts

1

1

24

4

Engineering

1

1

18

5

Diabetes

1

1

11

Karen Mezzi

×

14

Publications

458

Citations

13

H-Index

YearCitations

Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study

Karin Lisspers, Kjell Larsson, Christer Janson,

npj Primary Care Respiratory Medicine

2019

65

Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study

Christer Janson, Karin Lisspers, Björn Ställberg,

European Respiratory Journal

2020

62

Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry

Andrew I. Ritchie, Gavin C. Donaldson, Eric A. Hoffman,

American Journal of Respiratory and Critical Care Medicine

2024

46

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

Antonio Anzueto, C. Franz Vogelmeier, Κonstantinos Κostikas,

International Journal of COPD

2017

44

Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program

Ioanna Tsiligianni, Karen Mezzi, Sebastian Fucile,

COPD Journal of Chronic Obstructive Pulmonary Disease

2017

41

Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting

David Price, Dorothy L. Keininger, Madlaina Costa‐Scharplatz,

Respiratory Medicine

2014

34

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

Antonio Anzueto, Κonstantinos Κostikas, Karen Mezzi,

Respiratory Research

2018

33

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

Jadwiga A. Wedzicha, Dave Singh, Ioanna Tsiligianni,

Respiratory Research

2019

24

Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) and the French Society of Audiology (SFA) for Speech-in-Noise Testing in Adults

Charles-Alexandre Joly, Pierre Reynard, Karen Mezzi,

European Annals of Otorhinolaryngology Head and Neck Diseases

2021

24

The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study

Kjell Larsson, Christer Janson, Karin Lisspers,

International Journal of COPD

2021

23

Page 1